There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Cataracts, dry eyes, glaucoma, and other eye problems become more common with age. But these can be treated and even cured if ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... researchers are still looking for more accessible and affordable treatments for all forms of AMD. Since AMD is closely ...

Regenxbio (RGNX) announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal ...

This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely ...